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uring puberty, mouse mammary epithelial ducts
invade the stromal mammary fat pad in a wave of
branching morphogenesis to form a complex ductal
tree. Using pharmacologic and genetic approaches, we
ﬁnd that mammary gland branching morphogenesis re-
quires transient matrix metalloproteinase (MMP) activity
for invasion and branch point selection. MMP-2, but not
MMP-9, facilitates terminal end bud invasion by inhibiting
epithelial cell apoptosis at the start of puberty. Unexpectedly,
D
 
MMP-2 also represses precocious lateral branching dur-
ing mid-puberty. In contrast, MMP-3 induces secondary
and tertiary lateral branching of ducts during mid-puberty
and early pregnancy. Nevertheless, the mammary gland is
able to develop lactational competence in MMP mutant
mice. Thus, speciﬁc MMPs reﬁne the mammary branching
pattern by distinct mechanisms during mammary gland
branching morphogenesis.
 
Introduction
 
The mammary gland is changed during puberty from a
small, simply branched, relatively quiescent epithelial tissue
in the corner of the mammary stromal fat pad into a dynamic
tissue, in which ducts undergo dichotomous and lateral
branching and invade and fill the fat pad. In mice, this
hormone-dependent burst of mammary gland branching
morphogenesis begins with the formation of bulbous terminal
end buds (TEBs) at the invading front of epithelial ducts at
 
 
 
3 wk old. Several distinct mechanisms regulate branching
morphogenesis of the mammary gland. TEBs are driven
forward, invade the fat pad and undergo dichotomous
branching through bifurcation. Behind TEBs, mature ducts
sprout laterally to form secondary branches. In contrast to
the invasion of TEBs, where immature epithelium invades
directly into the adipose tissue of the fat pad, lateral
branches must invade through a barrier of myoepithelial
cells, basement membrane (BM) and stromal ECM that
surrounds mature ducts (Wiseman and Werb, 2002). The
invading epithelium must communicate with the stroma to
coordinate these events; however, the mechanisms by which
this cross talk regulates mammary gland branching morpho-
genesis are poorly understood (Affolter et al., 2003). Matrix
metalloproteinases (MMPs) are stromal factors that are ideally
positioned to regulate stromal–epithelial cross talk (Sternlicht
and Werb, 2001). MMPs could regulate mammary gland
branching morphogenesis by clearing a path for invading
ducts by degrading ECM barriers and permitting ductal
penetration into the mammary fat pad. MMPs also influence
cell signaling. They can change the extracellular microenvi-
ronment and thereby alter stromal–epithelial signaling. In
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addition, cleavage of growth factors, cytokines and cell–cell
adhesion proteins by MMPs can affect their activities.
MMPs can also release factors that are sequestered in the
ECM, thus, making them bioavailable. In three-dimen-
sional cultures of mouse mammary epithelial cells, MMP
activity is necessary for growth factor–induced branching,
and recombinant MMP-3 (stromelysin-1) is sufficient to
induce branching, in the absence of an added growth factor
(Simian et al., 2001). Similarly, an autoactivating MMP-3
transgene, targeted to the mouse mammary gland, acceler-
ates branching morphogenesis, inducing supernumerary
ductal branching and precocious appearance of lobular al-
veoli (Sympson et al., 1994; Witty et al., 1995). In con-
trast, introduction of exogenous tissue inhibitor of metallo-
proteinases-1 (TIMP-1) into pubertal mammary gland, via
a pellet, retards ductal invasion (Fata et al., 1999). There-
fore, MMPs may regulate branching morphogenesis in the
mammary gland by influencing stromal–epithelial cross
talk. However, how specific endogenous MMPs contribute
to the different aspects of elaboration of the ductal tree has
not been determined.
Here, we modified MMP activity broadly in pubertal fe-
male mice using either a small molecule inhibitor of MMPs,
GM6001, or by expressing TIMP-1, an endogenous inhibi-
tor of MMP activity, as a transgene or by deleting endo-
genous TIMP-1. Then, we used genetic analysis in mice
to elucidate specific roles for MMP-2 (gelatinase A) and
MMP-3 (stromelysin-1).
 
Results
 
MMPs have distinct expression patterns 
in the pubertal mammary gland
 
First, we determined where MMPs were expressed in the
mammary gland by in situ hybridization on sections of pu-
bertal mouse mammary tissue (Fig. 1). Four MMPs were
expressed in distinct locations in the mammary gland dur-
ing puberty. MMP-2 mRNA was concentrated primarily in
the periductal stroma and was weakly expressed by adipose
tissue. Surprisingly, its expression was reduced at sites of
initiating buds or side branches (Fig. 1 D). The mRNA for
MMP-14, the principal activator of MMP-2, (Will et al.,
Figure 1. Localization of MMPs-2, -3, -9, and -14 mRNA within the mammary gland. Mammary glands were taken at 50 d old and sectioned. 
(A–C, K, and O) Hematoxylin and eosin counterstain of mammary gland sections in G–J and N, respectively. Note the initiating lateral branch in 
A (black arrow) and TEB in B (black outlined arrow). In situ hybridization analysis was performed with the following antisense and sense probes 
(as indicated): (D–F) MMP-2, (G–I) MMP-14, (J, L, and M) MMP-9, and (N, P, and Q) MMP-3. Note the reduction in MMP-2, but not MMP-14 
mRNA, at the initiating lateral branch in the adjacent sections D and G (white outlined arrows); the localization of MMP-14 around the TEB in H 
(white arrow) and the spots of MMP-9 expression probably localized in macrophages in L (white arrow heads). Bars, 50  m.T
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1996) overlapped MMP-2 expression only in part. MMP-
14 was mainly stromal, but also present in the epithelium,
with no reduction at branch initiation sites; instead it was
highly concentrated within and around TEBs. MMP-3 was
exclusively stromal and located in periductal stroma and the
adipose tissue, with no difference at sites of initiating
branches. MMP-9 was expressed at low levels throughout
the gland in the epithelium and the stroma. There were
spots of concentrated MMP-9 (gelatinase B) mRNA that
correspond to macrophages.
 
Inhibiting mammary epithelial branching 
morphogenesis MMP activity by GM6001 
inhibits ductal invasion, but induces precocious 
lateral budding
 
To determine if MMP activity plays a role in branching
morphogenesis during pubertal mammary development, we
compared mammary glands from mice treated from 3.5 wk
old with a broad spectrum MMP inhibitor to controls
treated with the vehicle. GM6001 works well in inhibiting
MMP function in vivo (Alexander et al., 1996; Kheradmand
et al., 2002), and inhibits all MMPs tested with K
 
i
 
 values of
 
 
 
100 nM (Grobelny et al., 1992; Gijbels et al., 1994).
Ducts of mice treated with GM6001 showed much less in-
vasion than controls (Fig. 2, A, B, and H), and stopped
about where they were at the beginning of the treatment
(not depicted). An unexpected observation in the GM6001-
treated mice was that the mammary ducts displayed super-
numerary budding along the primary ducts compared with
the controls (Fig. 2 B, inset). These buds appeared to be lat-
eral branches that were initiated, but failed to elongate and
invade into the mammary fat pad.
The GM6001-treated mammary glands had fewer TEBs
than controls. In many of the GM6001-treated mice, some
primary ducts had no TEBs at their ends. Moreover, the
TEBs that formed were generally smaller than those of con-
trols. At 6.5 wk old, 1/11 treated mice had no TEBs. By 8.5
wk, the number with no TEBs had risen to 33% and by
10.5 wk, 100% of the GM6001-treated mice had no TEBs.
The control mice were normal. In all cases, serum estrogen
levels were normal and there was still space in the fat pad
(unpublished data).
To determine if the complete inhibition of ductal invasion
by GM6001 was reversible, we treated mice between 3.5
and 6.5 wk and then stopped the treatment. We found that,
after 2 and 4 wk of relief from GM6001 treatment, the
mammary ducts partially recovered (Fig. 2 H). This observa-
tion demonstrates that GM6001 did not produce irrevers-
ible damage, and that the ductal tree still had the potential
to recommence growth and invasion. GM6001 treatment
was stopped at 6.5 wk followed by 4 wk of recovery, 80% of
the mice had TEBs and space in the fat pad, indicating that
their ducts were still actively invading into the fat pad.
 
Transgenic overexpression of TIMP-1 attenuates 
mammary epithelial branching morphogenesis
 
As a second approach, we inhibited activity of most MMPs
using transgenic mice that overexpress human TIMP-1
driven by an 
 
 
 
-actin promoter (huTIMP-1 mice). We
found that the mammary ducts of mice that expressed
huTIMP-1 transgenes from both alleles (Tg/Tg) showed de-
creased invasion, taking 2 wk longer to reach the edges of
the mammary fat pad compared with wild-type controls
(Fig. 2 I). Thus, exogenous TIMP-1 retards, but unlike
GM6001, does not completely block ductal invasion. Inter-
estingly, the primary mammary ducts of mice with only one
transgene (Tg/
 
 
 
) grew to the same extent as the wild-type
glands (Fig. 2 I), suggesting that there is a threshold for
TIMP-1 to inhibit ductal invasion. TIMP-1 Tg/Tg mice
Figure 2. MMP inhibition disrupts mammary gland branching 
morphogenesis. (A and B) Mammary gland whole mounts from 
6.5-wk-old mice treated daily with (A) vehicle or (B) GM6001 from 
3.5 wk old. Note the extra ductal budding in the GM6001 treated 
mammary glands (inset). LN, lymph node; arrowheads, TEBs. 
Bar, 1 mm. (C–E) Mammary gland whole mounts from (C) nontrans-
genic control mice and (D) mice hemizygous and (E) homozygous 
for the  -actin human TIMP-1 transgene at 35 d old. n, nipple. 
Bar, 1 mm. (F and G) Primary mammary organoids grown for 7 d in 
the presence of EGF in collagen gels from (F) nontransgenic control 
mice or (G) huTIMP-1 transgenic mice. (H and I) Penetration of 
mammary ducts into fat pad of control mice, mice continually 
treated with GM6001 until sacrifice and mice that were treated with 
GM6001 from 3.5- to 6.5-wk-old using 8–12 mammary glands per 
data point (t test compared vehicle-control with mice continually 
treated with GM6001; H) and (I) nontransgenic control, Tg/  and 
Tg/Tg hu-TIMP-1 transgenic mice using 4–12 mammary glands per 
data point. Data are mean   SEM. t test compared Tg/  with Tg/Tg. 
(J) The percentage of branched organoids in response to 7-d treatment 
with EGF. Organoids were derived from hu-TIMP-1 transgenic mice, 
nontransgenic controls, or wild-type mice and grown in absence or 
presence of GM6001 or recombinant TIMP-1 as indicated. In all 
panels: ***, P   0.0005; **, P   0.005, unpaired, two-tailed t test.T
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showed only a slight effect on secondary branches, compared
with GM6001-treated mice (Fig. 2, C–E).
 
Inhibiting MMP activity in organotypic cultures 
attenuates mammary epithelial branching
 
The in vivo experiments with GM6001 and the huTIMP-1
transgene inhibited MMPs systemically, and not just in the
mammary gland. To determine if MMP inhibition acts lo-
cally on mammary cells, we isolated mammary organoids
(Simian et al., 2001) from wild-type or Tg/Tg 
 
 
 
-actin
huTIMP-1 mice and cultured them in collagen gels. Upon
addition of EGF or keratinocyte growth factor (FGF-7),
wild-type organoids extended several branches that con-
tained lumens. However, few huTIMP-1 organoids formed
branches, and, in those that did, the branches were shorter
and fewer in number (Fig. 2, F, G, and J; not depicted). Re-
combinant TIMP-1 and GM6001 added to organoid cul-
tures also inhibited branching in the same manner (Fig. 2 J).
Together, with our previous studies (Simian et al., 2001),
these experiments indicate that branching of mammary cells
is directly responsive to MMP inhibition.
 
TIMP-1 knockout mice have altered TEB morphology
 
If inhibition of MMP activity attenuates mammary ductal
invasion, then the absence of TIMP-1 could reduce MMP
action and change mammary morphogenesis. TIMP-1
mRNA is up-regulated during mouse mammary gland pu-
bertal development (Fata et al., 1999), but we found no
change in primary duct elongation in TIMP-1 
 
 
 
/
 
 
 
 mice
compared with controls, and only small increases in the
number of branch points (Fig. 3 D). This is not surprising
because at least three TIMP family members are expressed in
the mammary gland. However, TEBs were much larger in
TIMP-1 
 
 
 
/
 
 
 
 mice than their wild-type littermates (Fig. 3
B), indicating that TIMP-1 contributes to maintenance of
TEB morphology.
Together, with the results of GM6001, these data indicate
that MMP activity regulates aspects of branching morpho-
genesis in the mammary gland. Therefore, we investigated
which MMPs are involved.
 
MMP-2 regulates ductal invasion
 
MMP-2 is expressed in the stromal compartment around
mammary ducts during branching morphogenesis and is
present in an activated form (Fig. 1; Fata et al., 1999).
MMP-2 influences branching in the pseudoglandular stage
of lung development (Kheradmand et al., 2002), making it a
good candidate for regulating mammary branching. Al-
though MMP-2 
 
 
 
/
 
 
 
 mice show attenuated tumor growth
(Itoh et al., 1997, 1998), the females are able to nurture
their young. We compared mammary glands of age- and es-
trus-matched MMP-2 
 
 
 
/
 
 
 
, MMP-2 
 
 
 
/
 
 
 
, and wild-type
mice. Because there was no discernable heterozygous pheno-
type, we used the MMP-2 
 
 
 
/
 
 
 
 mice as controls. There was
no difference in the morphology of MMP-2 
 
 
 
/
 
 
 
 mammary
glands compared with littermate controls at 20 d old, indi-
cating that MMP-2 is not needed before pubertal develop-
ment. However, we found retarded invasion of the mam-
mary ducts of MMP-2 
 
 
 
/
 
 
 
 mice into the stromal fat pad at
30 d (Fig. 4, A, B, and I). This corroborates our in situ data
showing that mRNA for the activator of MMP-2, namely
MMP-14, is concentrated right at the invasive front of ducts
(Fig. 1). This corresponds to the site of highest MMP activ-
ity as seen by in situ zymography (unpublished data). This
phenotype was most evident in early puberty at 30 d old and
the difference was significant relative to the fat pad length.
However, the retardation was transient, and by 50 d, the dif-
ference was no longer significant (Fig. 4, C, D, and I).
Therefore, MMP-2 regulates only the initial events in ductal
invasion after puberty.
Then, we sought the mechanism by which MMP-2 might
regulate ductal penetration. TEBs formed properly and in a
timely manner in MMP-2 
 
 
 
/
 
 
 
 mice, indicating that pu-
berty was not delayed, and the glands responded to ovarian
hormones. MMP-2 has many ECM substrates (Sternlicht
and Werb, 2001), but we did not observe a build up of BM
proteins laminin-1 (Ln-1; Fig. 4, C and D) and collagen IV
(Coll IV), or interstitial ECM proteins (fibrillar collagens,
tenascin-C, fibronectin, and vitronectin) surrounding TEBs
or periductally (not depicted). TEBs increase in number by
bifurcation or dichotomous branching (Wiseman and Werb,
2002). However, there were no differences in the number of
TEBs in the mammary glands of MMP-2 
 
 
 
/
 
 
 
 mice com-
pared with controls (unpublished data).
Alternatively, MMP-2 could regulate cell proliferation
and/or apoptosis, both of which occur at high rates within
TEBs, to provide cells for ductal extension and for hollow-
ing out the ductal lumen, respectively (Humphreys et al.,
1996). We found no overt defects in TEB structure, size, as-
sociation with the stroma, or cell proliferation in MMP-2
 
 
 
/
 
 
 
 mice at 25 and 30 d (Fig. 4 and not depicted). How-
ever, the TEBs of MMP-2 
 
 
 
/
 
 
 
 mice had almost twice the
Figure 3. TIMP-1 is not necessary for ductal invasion or branching 
in the mammary gland. (A and B) Whole mounts of mammary 
glands of 42-d-old TIMP-1  /  (A) and TIMP-1  /  mice (B). Note 
the enlarged TEBs of TIMP-1  /  mice (inset). Bars, 1 mm. (C and 
D) Penetration of mammary ducts into fat pad (C) and number of 
branch points beyond the lymph node at 42 d old (D) of TIMP-1  /  
and TIMP-1  /  mice. Data are mean (C)   SEM or (D)   SD using 
four to eight mammary glands per data point.T
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level of apoptosis and activated caspase-3 compared with
controls (Fig. 4, G, H, and N; and not depicted). Thus,
MMP-2 supports epithelial cell survival, and in its absence
there may be too few cells available to form the growing
duct. These data also suggest that the mechanism of MMP-2
regulation of ductal morphogenesis and invasion of TEBs
occurs largely through path finding by a pushing action
from the increasing mass of proliferating cells, rather than
through a path clearing action of the MMP.
 
MMP-2 represses lateral budding
 
MMPs have long been thought to facilitate cell migration by
degrading ECM. However, we made the unexpected obser-
vation that MMP-2 mRNA was down-regulated along the
primary ducts at sites where new lateral branches initiate
(Fig. 1 D). This raises the question of whether MMP-2 has a
negative role in lateral branching. We determined the num-
ber of branch points arising from primary ducts as a func-
tion of ductal length (to account for the difference in
lengths). In the absence of MMP-2, mammary ducts had
more lateral branches than controls (Fig. 4 K). The branch-
ing defect was confined to lateral branching and did not af-
fect TEB bifurcation. Interestingly, the increase was con-
fined to secondary buds and branches arising from the
primary ducts (Fig. 4 L). There was no difference in terti-
ary branching (i.e., the frequency of ramified secondary
branches; unpublished data). Therefore the absence of
MMP-2 fosters the premature initiation of buds and small
branches. Importantly, this supernumerary branching only
began 
 
 
 
40 d old, about the time that the primary ducts ma-
ture, and was most evident 
 
 
 
50 d. The loss of MMP-2 ac-
celerated the rate at which the secondary branches appeared,
but by the time the mammary gland matured at 70 d old,
the MMP-2–null mice displayed a normal ductal tree. This
suggests that MMP-2 regulates the rate at which branches
appear, but does not affect the selection of branch sites.
Thus, MMP-2 has two roles: during early puberty it pro-
motes TEB invasion and supports cell survival, and later in
puberty it represses the rate of lateral branching. In contrast,
MMP-9 has no obvious role in mammary gland branching
Figure 4. MMP-2  /  mice have reduced ductal invasion and increased lateral branching. (A–D) Whole mounts of mammary glands of an 
(A and C) MMP-2  /  and (B and D) MMP-2  /  mice (A and B) 30 d old and (C and D) 50 d in estrus. Note supernumerary branching in 
D (inset). Example of ramified branch (arrows) and unramified branch or bud (arrowheads). Bars, 1 mm. (E–H) Sections through TEBs in mammary 
glands from 30-d-old (E and G) MMP-2  /  and (F and H) MMP-2  /  mice. (E and F) Immunohistochemistry for Ln-1. (G and H) TUNEL 
assay. Apoptotic cells are red. Bars, 25  m. (I–L) Penetration of mammary ducts of (I) MMP-2  /  and MMP-2  /  and (J) MMP-9  /  and 
MMP-9  /  mice, (K) number of branches per millimeter, and (L) number of unramified branches per millimeter at 50 d from primary 
mammary ducts of MMP-2  /  and  /  mice. Data are mean   SEM (I, K, and L) using 8–16 or (H) 4–8 mammary glands per data point. 
(M and N) Percentage of BrdU (M) or TUNEL (N) positive cells within TEBs of MMP-2  /  and MMP-2  /  30-d-old mice. Data are mean 
percent per TEB   SD. ***, P   0.0005; **, P   0.005; *, P   0.05, unpaired, two-tailed t test.T
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morphogenesis. Mice deficient for MMP-9, a close relative
of MMP-2, which is present and active (Fig. 1; Fata et al.,
1999), yielded no differences in ductal length or branching
(Fig. 4 J and not depicted).
MMP-3 regulates secondary duct formation 
during mammary branching morphogenesis
To initiate a new branch from a mature duct, it is necessary to
degrade the BM and stromal ECM underlying epithelial cells
that are primed for proliferation and invasion. Our previous
data suggest that MMP-3 degrades BM components, sheds
the extracellular domain of E-cadherin and regulates differen-
tiation of the adipogenic stroma in the mammary gland
(Sympson et al., 1994; Alexander et al., 1996; Thomasset et
al., 1998). MMP-3 also facilitates contraction of dermal fibro-
blasts during wound healing (Bullard et al., 1999).
MMP-3  /  mice showed a loss of function phenotype
(Fig. 5, A and B) that was the mirror image of the gain of
function phenotype that we described previously in WAP-
MMP-3 transgenic mice (Fig. 5, I and J; Sympson et al.,
1994). The heterozygote and wild-type mice were indistin-
guishable. In contrast to MMP-2  /  mice, the ductal
tree of mammary glands from MMP-3  /  mice was
much sparser, yet there were no differences in primary duc-
tal invasion compared with controls (Fig. 5, A, B, and L).
Both the frequency of branches and the total number of
branch points were greatly reduced in MMP-3  /  mice
(Fig. 5 M and not depicted). However, there was no differ-
ence in the number of TEBs (not depicted) between
MMP-3  /  glands and controls, indicating that MMP-3
was needed for lateral branching, rather than dichotomous
branching through TEB bifurcation. Furthermore, rami-
fied secondary branches were absent (Fig. 5 N), implying
that MMP-3 regulates both secondary and tertiary branch-
ing. This phenotype was transient and most evident
around 50 d old (Fig. 5, M and N). By 70 d old, the mam-
mary ductal tree in MMP-3  /  mice was indistinguish-
able from controls, indicating that other factors can com-
pensate for MMPs after 50 d.
At the onset of pregnancy, another phase of lateral
branching occurs from the mature mammary ducts and con-
tinues until mid-pregnancy when alveoli form on the ex-
panded ductal tree. Upon analysis, the ductal trees of mam-
mary glands from pregnant MMP-3  /  mice were much
sparser than controls at 6 and 9 d of pregnancy (Fig. 5,
C–F). Again, the phenotype was transient and by the 13 d of
pregnancy, there were no gross differences between knock-
outs and controls (Fig. 5, G and H). Thus, MMP-3 induces
secondary and tertiary lateral branching midway through
puberty and again in early pregnancy. Indeed, mammary
Figure 5. MMP-3 is required for lateral branching in the mammary gland. (A–H) Whole mounts of mammary glands of (A, C, E, and G) 
MMP-3  /  and (B, D, F, and H) MMP-3  /  mice at (A and B) 42 d old in estrus, (C and D) 6 d of pregnancy, (E and F) 9 d of pregnancy, 
and (G and H) 13 d of pregnancy. (I and J) Whole mounts of mammary glands of 70-d-old virgin (I) nontransgenic controls or (J) WAP-MMP-3 
transgenic mice. Bars, 1 mm. (K) Wild-type mammary gland stained for Ln-1. Note reduction in Ln-1 where lateral branches are budding 
(arrows). Bar, 25  m. (L–N) Penetration of ducts (L), number of total branches per millimeter (M), and number of ramified secondary branches 
per millimeter (N) from primary ducts of MMP-3  /  and MMP-3  /  mammary glands. Data are mean   SEM using 4–12 mammary 
glands per data point. ***, P   0.0005; **, P   0.005; *P,   0.05, unpaired, two-tailed t test.T
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glands of MMP-3  /  mice function and their pups have
no problems feeding (Lund et al., 2000).
MMP-2 and -3 have opposite effects on branching mor-
phogenesis during puberty. This raises the question of what
phenotype MMP-2; MMP-3 double null mice would show
in their mammary glands. We examined 11 mammary
glands from MMP-2  / ; MMP-3  /  mice. These
mammary glands resembled wild-type mammary glands, al-
beit with slightly delayed elongation of secondary branches
(unpublished data). These data suggest that these two
MMPs function in the epithelial microenvironment in dif-
ferent locations in a network of interacting pathways de-
signed to give the final branching pattern.
We found that the mammary glands of WAP-MMP-3
transgenic mice in which an autoactivating MMP-3 is tar-
geted to the mammary gland by the whey acidic protein pro-
moter show supernumerary lateral branching (Fig. 5, I and
J), in keeping with our earlier observations (Sympson et al.,
1994), but no change in the rate of primary ductal elon-
gation (not depicted). Consistently, the WAP-MMP-3
transgenic mice had supernumerary secondary and tertiary
branches (Sympson et al., 1994) that were greater in number
than those seen during the precocious branching seen in
MMP-2  /  mice, approaching the density of branching
seen in early pregnancy (Fig. 5, C and E).
For lateral branches to initiate, the sites must first be deter-
mined. Then, the epithelial cells must proliferate, migrate,
and invade through periductal stroma and ECM that sur-
round mature ducts. MMP-3 cleaves BM components in-
cluding Ln-1, nidogen, and Coll IV in the mammary gland
(Alexander et al., 1996). By immunohistochemistry, we ob-
served that MMP-3  /  and wild-type mammary glands
had similar levels of Ln-1 and Coll IV in the BM surround-
ing mature ducts. However, both Ln-1 and Coll IV were spe-
cifically degraded at sites of branch formation (Fig. 5 K and
not depicted). Although we could not locate the points
where branches failed to form, there were fewer sites of ECM
degradation along the ductal length in MMP-3  /  glands,
which is consistent with the reduced number of branch
points (Fig. 5, M and N). These data indicate that, unlike
down-regulation of MMP-2 (Fig. 4 K), which allows a more
rapid emergence of side branches that eventually total the
normal number, MMP-3 affects the selection of branch sites
by itself, and in excess, can trigger branch formation from
stem and progenitor cells that lie dormant along the ducts.
These data suggest that MMP-3 has three roles in epithe-
lial morphogenesis: it participates in the selection and spac-
ing of the lateral branches; it facilitates lateral branching by
degrading BM components and allowing epithelial cells to
invade into the stromal spaces; and it regulates the pheno-
type of stromal fibroblasts/preadipocytes, which in turn af-
fect the epithelium.
Discussion
Factors that initiate and control the outgrowth of individual
branches and reiteration of the branching process are just be-
ing elucidated in the mammary gland. Here, we have shown
that two MMPs have distinct functions in the correct execu-
tion of these steps. It is significant that MMPs are made al-
most exclusively in the mesenchymal compartment. As such,
they are critical mediators of the epithelial–mesenchymal
cross talk and the transient epithelial to mesenchymal transi-
tions needed for a branch to form (Affolter et al., 2003). In-
triguingly, MMPs may directly regulate migratory activity
by cleaving ECM molecules like laminin-5, turning it into a
motogen (Koshikawa et al., 2000). Our studies in vivo and
other studies suggest that programmed cell death contributes
to the morphology of branching organs, particularly in for-
mation of a lumen (Humphreys et al., 1996; Blatchford et
al., 1999; Debnath et al., 2002), and that MMPs mediate
these processes (Boudreau et al., 1995). At least part of the
function of the MMPs is to activate TGF- , which inhibits
lateral branching (Bottinger et al., 1997; Yu et al., 2001;
Ewan et al., 2002).
Our results show that, in mice, there are distinct mecha-
nisms and phases of mammary gland branching morpho-
genesis, both positive and negative, which are regulated by
MMPs. During early puberty, MMP-2 supports the inva-
sion of TEBs into the stromal fat pad, by protecting
against excessive apoptosis within TEBs. Later in puberty,
MMP-2 acts on the mature primary duct to repress exces-
sive secondary lateral budding and branching. In contrast,
MMP-3 acts on both primary and secondary ducts to in-
duce secondary and tertiary branch formation. Thus, the
MMP-3 loss of function analysis parallel the gain of func-
tion phenotypes, characterized by a significant delay in sec-
ondary and tertiary branching, is precisely the opposite of
the gain of function phenotype seen in mammary-targeted
MMP-3 transgenic mice, in which supernumerary lateral
branching and eventual tumor formation occur (Sympson
et al., 1994; Sternlicht et al., 1999).
MMP inhibitors regulate mammary morphogenesis
The demonstration that an exogenous huTIMP-1 transgene
inhibits mammary ductal invasion suggests that these effects
are due to the inhibition of a TIMP-1–inhibitable MMP. In
addition, the implantation of TIMP-1 pellets has a similar
effect locally, yet these pellets may result in unphysiologi-
cally high levels of TIMP-1 (Talhouk et al., 1992; Alexander
et al., 1996) or produce an inflammatory response to surgery
(Fata et al., 1999). Moreover, TIMP-1 can exert growth
promoting activity independent of its MMP inhibitory ac-
tivity (Baker et al., 2002). Nevertheless, we saw similar ef-
fects on mammary branching morphogenesis, both in vivo
and in vitro, with a synthetic MMP inhibitor, GM6001.
Thus, we conclude that, in the mammary gland, TIMP-1
acts by inhibiting the proteolytic activity of MMPs, and that
MMP activity is required for normal mammary gland
branching morphogenesis. GM6001 also induced the regres-
sion of TEBs, yet this was not obvious in the absence of
MMP-2 or -3 nor in TIMP-1–overexpressing transgenic
mice, suggesting that an unidentified MMP plays a role in
TEB maintenance. TIMP-1 and GM6001 have different in-
hibitory activities against specific MMPs. TIMP-1 does not
inhibit MMP-14 or MMP-19 at physiological concentra-
tions, and is less effective at inhibiting MMP-2 than MMP-3.
On the other hand, high concentrations of GM6001 may
inhibit ADAM-TS metalloproteinases. The response of the
ducts to MMP inhibition was also dose dependent. A dou-T
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ble dose of the huTIMP-1 transgene was needed to suppress
normal ductal development.
That the loss of TIMP-1 only produced a mild gain of
function phenotype is not surprising because there are four
TIMP family members, each of which is expressed in the
mammary epithelium and adipogenic stroma (Fata et al.,
1999; Alexander et al., 2001), as well as other endogenous
MMP inhibitors (Welm et al., 2002). Thus, MMP-medi-
ated effects on the mammary gland are still controlled, de-
spite the absence of TIMP-1. Surprisingly however, the
mammary phenotype in the TIMP-1–deficient mice was less
pronounced than that seen in mice with only a 50% de-
crease in their normal TIMP-1 levels due to an antisense
TIMP-1 transgene. Consistent with the notion that MMPs
influence ductal elongation and branching, these partially
TIMP-1–deficient mice had longer ducts and supernumer-
ary branching compared with controls and no difference in
TEB size (Fata et al., 1999). Thus, their more pronounced
phenotype may be due to compensatory responses, the anti-
sense repression of additional TIMPs, or strain-specific dif-
ferences in sensitivity to MMP inhibition.
Invasion of TEBs requires MMP-2 activity
MMP-2 regulates the initial invasion of TEBs into the fat
pad. MMP-2 has been implicated in the induction of apop-
tosis through destruction of ECM, leading to altered adhe-
sion (anoikis; Lund et al., 1996; Roberts et al., 2002) or by
allowing infiltration of toxic immune cells (Wielockx et al.,
2001). In contrast, MMP-2 promotes cell survival in the
TEB, which is a site of both proliferation and cell death.
Thus, MMP-2 may release survival factors sequestered by
binding proteins or the ECM. However, TEBs are multilay-
ered and the apoptotic cells are found close to the lumen
(Fig. 6; Humphreys et al., 1996), which suggests that these
cells are not dying by anoikis. Thus, other potential sub-
strates, such as insulin-like growth factor binding proteins,
which are MMP-2 substrates (Fowlkes et al., 1999) that can
be inhibited from signaling in vivo by MMP inhibitors
(Martin et al., 1999), may be responsible for the survival-
promoting effects of MMP-2. The enlarged TEBs of the
TIMP-1–deficient mammary glands may also be related to a
reduction in apoptosis due to increased MMP-2 activity,
leading to an overabundance of cells. MMP-2 presumably
allows sufficient cells to accumulate for ductal extension to
ensue. Although it is likely that cell migration is important
for branching and the invasion of the epithelial cell layer
into the fat pad, our results suggest that branches may be
pushed outwards by cell division. This does not preclude the
possibility that they are also pulled out by migratory cells.
MMP-2 may have functions that facilitate TEB invasion
in addition to protection from apoptosis. Although we did
not detect a build up of Ln-1 and Coll IV at the invading
front of the TEBs, there may be a build up of other ECM
components. MMP-2 produces a bioactive fragment from
 2 chain of laminin-5 that induces breast epithelial cells to
migrate in vitro (Giannelli et al., 1997). MMP-2 is impor-
tant in angiogenesis (Itoh et al., 1998; Kato et al., 2001) and
may regulate blood vessel formation for the newly formed
mammary epithelium.
MMP-14 is an activator of MMP-2 (Will et al., 1996; for
review see Sternlicht and Werb, 2001). The localization of
MMP-14 (a membrane-bound MMP) at the invading front
of TEBs, together with the requirement for MMP-2 in TEB
invasion, strongly suggests that MMP-14 anchors MMP-2
activity at this invading front. Moreover, TIMP-2 is part of
the MMP-14 complex that activates MMP-2, and in con-
trast to TIMP-1, implantation of TIMP-2 Elvax pellets in-
creases ductal invasion locally (Fata, J.E., and R. Khokha,
personal communication). Thus, MMP-14 and TIMP-2
may localize and activate MMP-2 at the invasive front of
TEBs and so assist the invasion of primary ducts.
MMPs differentially regulate lateral branching
We predicted that an MMP capable of BM degradation
would be expressed at branch initiation points. Instead, we
found that expression of MMP-2 is specifically down-regu-
lated at branch points. Because supernumerary branches ap-
peared in MMP-2  /  mice and in mice treated with
GM6001, the selection of active sites for branching may be
regulated by MMP-2, such that that potential branch sites
that still express MMP-2 are inhibited. TGF  is activated by
MMP-2 (Yu and Stamenkovic, 2000) and is a potential
effector of MMP-2–mediated branch inhibition, because
TGF  signaling represses lateral branching and proliferation
in the mammary gland (Kordon et al., 1995; Joseph et al.,
1999). Importantly, regulation of epithelial invasion or mor-
Figure 6. Model for different phases of mammary gland branching morphogenesis. Before puberty, the mammary epithelial is small and 
simply branched. In response to the release of estrogen (E) and growth hormone (GH), at  3 wk old TEBs form. MMP-2 is then involved in 
inducing TEBs to invade and the ducts begin to fill the fat pad by branching dichotomously through bifurcation. At  6–8 wk old, the mammary 
ducts branch laterally. This process is suppressed by MMP-2 and induced by MMP-3 and may be related to changes in the response of the 
gland to progesterone (P) and prolactin (PRL). The fat pad is filled with ducts at  10 wk old and is relatively quiescent until pregnancy, when 
there is another wave of lateral branching that is regulated by MMP-3, P, and PRL before the formation of lobular alveoli.T
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phogenesis by MMP-2 depends very much on context, be-
cause at different sites and phases, MMP-2 promotes (at the
invasion front of TEBs) and inhibits (from mature ducts)
epithelial invasion. Thus, MMP-2 differentially regulates ep-
ithelial morphogenesis depending on its microenvironment.
In contrast to MMP-2, our data from knock out and
transgenic mice demonstrate that MMP-3 induces second-
ary and tertiary ducts in the mammary gland both midway
through puberty and again at pregnancy. The extrusion of
lateral branches from mature ducts requires that the initiat-
ing cells break though BM and a thick layer of interstitial
ECM (Wiseman and Werb, 2002). Indeed Ln-1 protein lev-
els are reduced at sites of initiating branches (Fig. 5 K).
Thus, MMP-3 may break down the physical BM barrier to
allow lateral branching. Interestingly, Ln-1 is produced by
myoepithelial cells and stabilizes the polarity of epithelial
cells (Gudjonsson et al., 2002). Because epithelial cells depo-
larize when initiating new branches (O’Brien et al., 2002).
MMP-3 may degrade Ln-1 to allow epithelial depolarization
and migration at bud initiation sites. MMP-3 also cleaves
the ectodomain of E-cadherin, which inhibits E-cadherin
function and could induce invasion of breast epithelial cells
(Lochter et al., 1997; Noe et al., 2001).
The requirement for MMP activity for ductal elongation
and lateral branching was transient in all cases except treat-
ment with GM6001. This suggests that MMPs facilitate de-
velopmental processes, possibly by increasing bioavailability
of signaling factors or loosening the ECM barrier, but are
not absolutely required for these events. Alternatively, there
may be compensation by other proteases. The delays ob-
served may be because the compensatory protease is more
inefficient than the original MMP, but can eventually com-
plete the task. This may be why the effects of GM6001 were
not transient: there was no MMP activity to compensate.
Mammary gland branching morphogenesis occurs 
in distinct phases
The mammary gland is patterned by distinct mechanisms:
ductal invasion, bifurcation of TEBs, and lateral branching
from mature ducts. MMPs regulate at least two of these
mechanisms, and yet the requirement for MMPs becomes
apparent at different ages. MMP-2 was required for invasion
at 3–4 wk old, whereas MMP-2 and -3 were needed to regu-
late lateral branching after 6 wk old. It is interesting that the
hormonal pathways (prolactin and progesterone) that con-
trol tertiary branching in the mammary gland (Hovey et al.,
2002) are also up-regulated at this time. Expression of pro-
lactin and progesterone receptor mRNAs increase in the
mammary gland at 6 and 8 wk old, respectively (Hovey et
al., 2001) and progesterone receptor protein is redistributed
between 6 and 12 wk old (Seagroves et al., 2000). This sug-
gests that midway through puberty, ducts undergo a matura-
tion phase, regulated by MMPs and hormones, which mani-
fests as the ability to sprout and ramify lateral ducts. Thus,
we propose that mammary gland branching morphogenesis
occurs in distinct phases (Fig. 6). First, at around 3 wk old,
TEBs are formed in response to estrogen and growth hor-
mone, and ducts begin to invade in an MMP-2–dependent
manner. Then,  6 wk old and in response to prolactin and
progesterone, ducts mature and sprout lateral branches,
which is dependent on both MMP-2 and -3. Then during
early pregnancy, another round of MMP-3–dependent lat-
eral branching occurs, which also requires progesterone and
prolactin (Hovey et al., 2002).
Unlike the Drosophila trachea, branch outgrowth and
elongation in the mammary gland are associated with cell di-
vision, and, thus, the former must somehow be coupled to
the latter. Stem cells capable of repeated cycles of growth are
embedded in the ductwork (Welm et al., 2002). This phe-
nomenon appears to occur in Drosophila, where tracheo-
blasts repopulate the tracheal system after each larval state
(Sato and Kornberg, 2002).
Our work separates branching morphogenesis into pheno-
typically recognizable stages each regulated by distinct MMPs.
This prototype may facilitate mapping the factors that have al-
ready been found to regulate these different branching mecha-
nisms into a regulatory network, which, so far, has been un-
feasible (Hennighausen and Robinson, 2001).
Much of what we have learned from the way MMPs regu-
late mammary branching morphogenesis can be applied to
increasing our understanding of how MMPs regulate epithe-
lial morphogenesis and invasion in human diseases, such as
metastatic cancer. We have found that their action depends
greatly on context, and different MMPs can have opposing
effects. Our challenge is now to elucidate the detailed mech-
anisms underlying these biologic events.
Materials and methods
Mice
Mice used for the GM6001 experiment were Balb/C. GM6001 (3-[N-
hydroxycarbamoyl]-[2R]-isobutylpropionyl-L-tryptophan methylamide) was
synthesized according to Grobelny et al. (1992) and administered daily i.p.
at 100 mg/kg body weight as a 20 mg/ml slurry in 4% carboxymethylcellu-
lose in 0.9% PBS from 3.5 wk old until indicated. Controls were treated
with a daily injection of 4% carboxymethylcellulose. We analyzed 8–12
treated and control mice for each time point.
The transgenic mice expressing a human TIMP-1 transgene under the
control of the  -actin promoter have been described previously (Alexander
et al., 1996) and were on a CD-1 background. Wild-type mice were non-
transgenic siblings, Tg/  transgenics were mice resulting from transgenic  
wild-type crosses and Tg/Tg transgenic mice were mice resulting from
transgenic   transgenic crosses, in which both parents had only had trans-
genic offspring when mated with a wild-type partner. We analyzed 33 Tg/
Tg mice and 40 controls. Mice carrying a targeted null mutation of the
TIMP-1 gene were on the Balb/C background and have been described
previously (Soloway et al., 1996) and were compared with heterozygous
littermates. We analyzed 14 TIMP-1  /  mice and 11 littermate controls.
Mice carrying a targeted null mutation of MMP-2 have been reported
previously (Itoh et al., 1997) and then backcrossed into the FVB/n back-
ground for over five generations and compared with heterozygous litter-
mates. We analyzed 42 MMP-2  /  mice and 45 littermate controls. Mice
carrying a targeted null mutation in the MMP-3 gene have been described
previously (Mudgett et al., 1998) and were on a mixed out bred back-
ground and were compared with heterozygous littermates. We analyzed
36 MMP-3  /  mice and 22 littermate controls. Transgenic WAP-MMP-3
mice have an auto-activating rat MMP-3 transgene targeted to the mam-
mary epithelium by the mouse WAP gene promoter, they were on the CD-1
background and have been described previously (Sympson et al., 1994)
and were compared with wild-type mice from transgenic crosses. These
samples were provided by C. Sympson (Lawrence Berkeley Laboratory,
Berkeley, CA). We analyzed 25 WAP-MMP-3 mice and 22 controls.
Mammary gland whole mount preparation and 
morphometric analysis
Female mice were killed during estrus as determined by vaginal smear
(Rugh, 1990). The No. 4 (inguinal) mammary glands were whole mounted
onto glass slides, stained with alum carmine, and cleared of fat as de-T
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scribed previously (Sympson et al., 1994). Whole mounts were photo-
graphed at 8  on a stereo microscope (model MZFL111; Leica) equipped
with a digital camera (model DXM1200; Nikon) and accompanying soft-
ware (ACT-1; Nikon) and images transferred to Adobe Photoshop. NIH Im-
age software was used for morphometric analysis. Ductal penetration was
the average of the mean length of straight lines from the nipple to the ends
of the three longest ducts of each mammary gland. The number of
branches per millimeter of duct was the average of the mean number of
unbranched and ramified branches on three of the longest primary ducts as
a function of the actual length of those ducts. The number of branch points
was the mean number of branch points beyond a vertical line through the
center of the lymph node of each mammary gland.
Immunohistochemical analysis
Antigen retrieval for rabbit polyclonal antilaminin (1:500; Caltag) was di-
gestion with 0.4% pepsin (Sigma-Aldrich), pH 5.2, for 90 min at 37 C. En-
dogenous biotin binding and peroxidase activities were blocked with Avi-
din-Biotin blocking kit (Vector Laboratories) and 3% H2O2, respectively.
Primary antibody localization was with biotinylated anti–rabbit IgG
(1:250; Sigma-Aldrich), then amplification with ABC reagent (Vector Labo-
ratories). For chromogenic visualization of antigen, Fast DAB (Sigma-
Aldrich) was the substrate for HRP with hematoxylin (Zymed Laboratories)
counterstain. For fluorescent visualization, tyramide reagent (NEN Life Sci-
ence Products) was followed by visualization with Alexa 488–streptavidin
(1:350; Molecular Probes). Brightfield, fluorescence, and darkfield images
were obtained with a microscope (model DMR HC; Leica) using 10 /0.30
and 20 /0.50 HC Plan Fluotar and 40 /0.75 Plan Apochromat air objec-
tives. Color digital images were captured to Adobe Photoshop using a
cooled CCD digital camera (model SPOT 100; Diagnostic Instruments) and
accompanying SPOT software. To ensure consistent exposure of adjacent
sense and antisense in situ hybridization sections, darkfield images were
captured using manual R/G/B and gain settings of 0.25/0.4/3 and 16, re-
spectively. Otherwise, automated exposure settings were used after white
balance for all other images.
Analysis of cell proliferation and apoptosis within TEBs
TEBs were defined by their morphology (including an open lumen) and
their position. For cell proliferation assays, 30-d-old MMP-2  /  and  / 
littermates were injected i.p. with 2 mg/mouse BrdU (Sigma-Aldrich) 2 h
before harvest. PFA-fixed No. 4 mammary glands were paraffin embedded
and sectioned for the cell proliferation and apoptosis assays. Cells that in-
corporated BrdU were localized using the BrdU staining kit (Zymed Labo-
ratories). We counted the number of BrdU positive cells as a percentage of
total number of cells within each TEB. At least 10 TEBs from three mice
(i.e., 2–4   10
3 cells) were counted for each point. To analyze apoptosis,
the ApoptagRed kit (Intergen; based on the TUNEL assay) was used and
mounted in DAPI containing Vectorshield mounting medium (Vector Lab-
oratories). We defined apoptotic cells as the red stained cells and deter-
mined their number as a percentage of the total number of cells within a
TEB. Two to three adjacent sections through over 20 TEBs from three mice
(i.e., over 10
4 cells) for each point were assayed.
In situ hybridization analysis of mRNA
The probes and the techniques used for the in situ hybridization have been
described previously (Lund et al., 1996, 1999).
Preparation of primary mammary organoids
Primary mammary epithelial organoids consist of epithelial, myoepithelial
cells, and some periductal stromal cells. They were prepared from 10-wk-
old virgin mice by manual and enzymatic digestion, embedded in type I
collagen gels and cultured as described previously (Simian et al., 2001).
EGF (Collaborative Research) was used at a final concentration of 50 ng/
ml. GM6001 was a gift from R. Galardy (Glycomed Corp, Alameda, CA)
and dissolved at 100 mM in dimethylsulfoxide and used at a final concen-
tration of 10  M. TIMP-1 was used at 150 nM. It was purified from condi-
tioned medium of confluent cultures of baby hamster kidney cells stably
transfected with human TIMP-1 (University Technologies International,
Inc.), and maintained in DME supplemented with 0.2% lactalbumin hy-
drolysate and penicillin/streptomycin according to (Howard et al., 1991).
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